CA-WILSHIRE/XTP
29.8.2024 15:01:32 CEST | Business Wire | Press release
Wilshire Advisors LLC (“Wilshire”), a leading global financial services firm, today announced that it has joined forces with XTP Implementation Services (“XTP”), a tech-enabled and data-driven specialist focused on improving transparency, reducing risk, enhancing investment governance, and increasing net returns for institutional investors globally. Through this partnership, which was effectuated by an acquisition of XTP by Wilshire, with simultaneous reinvestment in Wilshire by former XTP shareholders, XTP will continue to operate independently under its existing leadership team and brand. Financial terms of the transaction were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240828886722/en/
XTP is a market leader in cost transparency analytics, with a 20-year history of serving public and private investors, including pension funds, insurance companies, sovereign wealth funds, investment consultants, outsourced chief investment officers, endowments and foundations, and family offices. With more than $3 trillion in assets analyzed across 10,000 portfolios in North America and Europe, XTP helps its clients reduce investment-related costs and risks while enhancing governance. Combining deep industry experience and proprietary software, benchmarking databases, and forensic capabilities allows XTP to identify optimization potential across the investment value chain of public and private market portfolios. XTP clients benefit from a risk-free increase in net returns.
Andy Stewart, CEO at Wilshire, said: “We are excited to partner with XTP and bring its cost and risk-reduction services to our institutional clients, which will benefit from the power of its sophisticated insights and solutions. Throughout our discussions, it was clear that Wilshire and XTP share a holistic, client-centric approach that seeks to align our success with that of our clients. On behalf of Wilshire, I extend a warm welcome to the talented XTP team and look forward to collaborating for the benefit of our combined client base.”
Philipp Henrich, Founder and CEO at XTP, said: “We welcome our partnership with Wilshire, whose solutions, clients, and geographic footprint are complementary to ours. By joining forces, we have the opportunity to leverage the resources of a global service provider with a very strong presence in North America. This will enable us to offer our capabilities to an expanded client base while continuing to provide our valued, long-standing customers personalized, mission-critical support. We could not be more optimistic about this new, bright chapter for XTP with Wilshire alongside us.”
Jason Schwarz, President and Deputy CEO at Wilshire, said: “Institutional investors worldwide are more focused than ever on efficiency and transparency, seeking to better understand, disclose, and manage the true costs of their investments. XTP has an impressive 20-year track record and unmatched ability to identify cost and risk-reduction opportunities and translate those insights into enhanced returns. By bringing together XTP’s proprietary capabilities and Wilshire’s multifaceted platform, we will be even better positioned to empower clients with solutions that address their top concerns and deliver even more value.”
Solomon Partners and Kirkland & Ellis LLP served as financial advisor and legal advisor to Wilshire, respectively. XTP shareholders were advised by DLA Piper.
About Wilshire
Wilshire is a leading global financial services firm and trusted partner to approximately 500 leading institutional investors and financial intermediaries. Our clients rely on us to improve investment outcomes for a better future. Wilshire advises on over $1.4 trillion in assets and manages over $121 billion in assets as of March 31, 2024. Wilshire is headquartered in the United States with offices worldwide. More information on Wilshire can be found at www.wilshire.com.
About XTP
XTP is a specialist consultant focusing on transparency, cost, and risk. XTP actively supports large institutional asset owners globally in turning data into measurable results. By creating full cost transparency in public and private market portfolios XTP assures contract compliance, eliminates process inefficiencies and operation risks, and optimizes costs without changing the existing investment set-up. More information on XTP can be found at www.xtp-group.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828886722/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom